


**DATE:** April 9, 2025

**TO:** Torrance Memorial Medical Staff Members & Hospital Departments

**FROM:** Oren Zaidel, M.D., Chief of Staff 

**SUBJECT:** Medical Executive Committee Meeting Action Items

---

The following items were approved or presented for information by the Medical Executive Committee on April 8, 2025:

**ANESTHESIA DEPARTMENT – March 12, 2025**

A. Informational: ULR51-Dermabond Allergy

**EMERGENCY DEPARTMENT – March 20, 2025**

A. Informational: Event Notification: RCA202-Antibiotics Not Given

**MEDICINE DEPARTMENT – March 12, 2025**

A. Informational: Event Notification: RCA199-Sentinel Event

**SURGERY DEPARTMENT – April 4, 2025**

A. Informational: Event Notification: ULR63-Request for Intra-Op Consult Went Unanswered Requiring Return to Surgery

**CREDENTIALS COMMITTEE – March 27, 2025 and April 7, 2025**

A. Revision to Privilege Cards & Reference Document to Accept International Activity

**INFECTION PREVENTION/P&T COMMITTEE – April 1, 2025**

- A. Criteria for IV to Per Oral Conversation
- B. Empiric Antibiotic Treatment Guidelines
- C. Revised Critical Care Management Policy/Procedure entitled, “Ventilator Weaning Protocol”
- D. Revised Order Set: Med Only Symptom Triggered Management for MSU, Mild CIWA-Ar Score
- E. 5-Year Review Anesthesia Order Sets
  - Epidural Continuous and PCEA Infusion Orders
  - Peripheral Nerve Block Infusion
  - Post-Anesthesia Care Unit Pediatric  $\leq$  13 years old (PACU)
  - Post-Op Intraspinal opiate Analgesia Orders (Main OR)
- F. Revised Nicardipine and Clevidipine Drip Changes and Guidelines
- G. Revised Therapeutic Interchange-Respiratory Inhalers
- H. Revised Medication Management Policy/Procedure entitled, “Medication Order Screening and Clarification”
- I. Revised Order Set: ECMO Maintenance

**INSTITUTIONAL REVIEW BOARD – March 17, 2025**

**A. Continuing Review**

1. PulseRider Aneurysm Neck Reconstruction Device (ANRD). Paula Eboli, M.D., PI
2. The STAR Study: Outcomes and Safety in Patients Treated with STAR and Deferred Stenting After Unsuccessful CTO PCI. R. Michael Wyman, M.D., PI

**B. Internal Serious Adverse Event**

1. The COMPLETE TAVR Study: A Randomized, Comparative Effectiveness Study of Staged Complete Revascularization with Percutaneous Coronary Intervention to Treat Coronary Artery Disease vs Medical Management Alone in Patients with Symptomatic Aortic Valve Stenosis Undergoing Elective Transfemoral Transcatheter Aortic Valve Replacement. Salman Azam, M.D., PI

**C. Informational: Reliance Agreement**

1. ARTEMIS EX6018-4979: Effects of Ziltivekimab versus placebo on cardiovascular outcomes in patients with acute myocardial. J. Christopher Matchison, M.D., P

**D. Informational: Study Closure**

1. Nurses' Professional Quality of Life and Resilience Amid COVID-19. Jolene Smeltzer, PhD, RN, PI

If there are any questions, please contact Genny Schauwecker at extension 27555.

**Distribution:**

TMMC Website – For Medical Staff Members  
Medical Staff Services/Performance Improvement Department  
Dan Bauman, Clinical Informatics  
Kathy Hagemeier, Nursing Administration  
Amy Hellinga, Clinical Informatics  
Sharon Higgins, Clinical Informatics  
Maki Jerden, N.P., Wound Ostomy  
Anne Kienberger, Clinical Informatics  
TMMC Managers